drugset / Trial / NCT02348606

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348606

Phase 3 Completed 476 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm parallel group study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.

Timeline

Start
2015-05
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Solriamfetol Small molecule 37.5 mg
Comparator Solriamfetol Small molecule 75 mg
Comparator Solriamfetol Small molecule 150 mg
Comparator Solriamfetol Small molecule 300 mg